Evidence map›Paper›PMID 36033582›Full record

ArticleBioMed research international2022

From Cognitive MR-Targeted Fusion Prostate Biopsy to Radical Prostatectomy: Incidence and Predictors of Gleason Grade Group Upgrading in a Chinese Cohort.

Huaqing Yan, Yiming Wu, Xiaobo Cui, Sinian Zheng, Peng Zhang, Rubing Li

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The prognostic value ofFrontiers in oncology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Huaqing YanDepartment of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang 315000, China.ORCID https://orcid.org/0000-0001-9994-720X
Yiming WuDepartment of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang 315000, China.
Xiaobo CuiDepartment of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang 315000, China.
Sinian ZhengDepartment of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang 315000, China.
Peng ZhangDepartment of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang 315000, China.
Rubing LiDepartment of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang 315000, China.ORCID https://orcid.org/0000-0002-3269-6116
Ningbo Medical Center Lihuili Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To access the incidence and predictors of Gleason grade group upgrading from cognitive MR-targeted fusion prostate biopsy to radical prostatectomy in a Chinese cohort. Materials and Methods: We included 199 patients in our institution between January 2016 and June 2021. Multivariable logistic regression model and nomograms were utilized to analyze the collected data. Results: The concordance rate of biopsy Gleason grade group and radical prostatectomy was 50.3% (100 in 199). Upgrading occurred in 80 (40.2%) patients and 37 (68.5%) patients have an upgrading Gleason grade group when the biopsy Gleason grade group was 1. Multivariable logistic regression models were established to analyze the incidence and predictors of Gleason grade group upgrading from cognitive MR-targeted fusion prostate biopsy to radical prostatectomy. Biopsy Gleason grade group, prostate volume, and patient year were confirmed to be individual predictors of upgrading. Based on the logistic regression models, nomograms for predicting probability of prostate Gleason grade group upgrading were generated. Conclusions: We established a logistic regression model to predict the accuracy of prostate biopsy GG and provide the probability of upgrading. Clinicians should be more cautious when deciding the treatment strategy especially for prostate cancer biopsy GG1 patients. Future studies should expand the sample size and include more variables to improve the accuracy of predicting upgrading and prostate cancer early screening program is urgently needed in our city in China.

Indexed as

ProstateProstatic NeoplasmsBiopsyChinaCognitionHumansImage-Guided BiopsyIncidenceMaleNeoplasm GradingProstatectomyProstate-Specific AntigenRetrospective StudiesProstate-Specific Antigen

Identifiers

PMID36033582
PMCPMC9402296
OpenAlexW4292343356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.